• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

东亚经皮冠状动脉介入治疗患者缺血和出血风险评估工具的开发和验证。

Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention.

机构信息

Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.

Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.

出版信息

Thromb Haemost. 2019 Jul;119(7):1182-1193. doi: 10.1055/s-0039-1688792. Epub 2019 May 12.

DOI:10.1055/s-0039-1688792
PMID:31079414
Abstract

BACKGROUND

The ischemic/bleeding risk of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is still uncertain. We sought to develop a tool to predict ischemic and bleeding events in East Asians receiving 2nd generation drug-eluting stents (DESs) PCI.

METHODS

A pooled cohort of 13,172 East Asian patients receiving PCI with 2nd generation DES (the Grand DES cohort) was analyzed to develop a scoring system. A net score was calculated by subtracting the bleeding score from the ischemic score. External validation was performed in the HOST-ASSURE and NIPPON trials.

RESULTS

Among the total population, ischemic and bleeding events occurred in 195 patients (1.5%) and 166 patients (1.3%), respectively. The score to predict ischemic events included previous myocardial infarction (MI) or PCI, presentation as acute MI, anemia, stent diameter < 3 mm, and total stent length of ≥30 mm, while that for bleeding events included older age, low creatinine clearance, and anemia. C-statistics of the ischemic and bleeding model was 0.708 and 0.665, respectively. Patients with a net score of ≥1 had a higher ischemic risk compared with bleeding risk, and patients with a net score of ≤-1 had a higher bleeding risk compared with ischemic risk. The validation cohort showed a C-statistic of 0.647 for ischemic events and 0.633 for bleeding events.

CONCLUSION

We developed a tool to predict ischemic and bleeding events in East Asian patients received PCI with 2nd generation DES. This system can be used to assess clinical event risks, and to determine the adequate duration of DAPT in East Asians.

摘要

背景

经皮冠状动脉介入治疗(PCI)后双联抗血小板治疗(DAPT)的缺血/出血风险仍不确定。我们旨在开发一种工具,以预测东亚人群接受第二代药物洗脱支架(DES)PCI 后的缺血和出血事件。

方法

对接受第二代 DES 行 PCI 的东亚患者的汇总队列(Grand DES 队列)进行分析,以建立评分系统。通过从缺血评分中减去出血评分来计算净评分。在 HOST-ASSURE 和 NIPPON 试验中进行了外部验证。

结果

在总人群中,分别有 195 例(1.5%)和 166 例(1.3%)患者发生缺血和出血事件。预测缺血事件的评分包括既往心肌梗死(MI)或 PCI、急性 MI 表现、贫血、支架直径<3mm 和总支架长度≥30mm,而预测出血事件的评分包括年龄较大、肌酐清除率较低和贫血。缺血和出血模型的 C 统计量分别为 0.708 和 0.665。净评分≥1 的患者发生缺血的风险高于出血风险,而净评分≤-1 的患者发生出血的风险高于缺血风险。验证队列中,缺血事件的 C 统计量为 0.647,出血事件的 C 统计量为 0.633。

结论

我们开发了一种用于预测东亚人群接受第二代 DES 行 PCI 后缺血和出血事件的工具。该系统可用于评估临床事件风险,并确定东亚人群中 DAPT 的合适持续时间。

相似文献

1
Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention.东亚经皮冠状动脉介入治疗患者缺血和出血风险评估工具的开发和验证。
Thromb Haemost. 2019 Jul;119(7):1182-1193. doi: 10.1055/s-0039-1688792. Epub 2019 May 12.
2
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗1年后双联抗血小板治疗获益与风险预测规则的制定与验证
JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775.
3
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.双联抗血小板治疗的持续时间基于冠状动脉支架置入术后的缺血和出血风险。
J Am Coll Cardiol. 2019 Feb 26;73(7):741-754. doi: 10.1016/j.jacc.2018.11.048.
4
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.在不受限制的经皮冠状动脉介入治疗人群中使用双联抗血小板治疗评分预测缺血和出血事件。
Circ Cardiovasc Interv. 2018 Oct;11(10):e006853. doi: 10.1161/CIRCINTERVENTIONS.118.006853.
5
Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction.验证 DAPT 评分在急性心肌梗死患者中延长双联抗血小板治疗的效果。
Hellenic J Cardiol. 2019 Sep-Oct;60(5):296-302. doi: 10.1016/j.hjc.2018.05.007. Epub 2018 May 25.
6
The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents.东亚人群经皮冠状动脉介入治疗中仅使用第二代药物洗脱支架时双联抗血小板治疗评分的验证。
Catheter Cardiovasc Interv. 2021 Sep;98(3):E332-E341. doi: 10.1002/ccd.29682. Epub 2021 Apr 5.
7
Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.验证双联抗血小板治疗评分在来自 3 项日本经皮冠状动脉介入治疗研究的大型汇总队列中的效用。
Circulation. 2018 Feb 6;137(6):551-562. doi: 10.1161/CIRCULATIONAHA.117.028924. Epub 2017 Oct 5.
8
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.经药物洗脱支架 PCI 术后的冠状动脉血栓形成和大出血:PARIS 风险评分。
J Am Coll Cardiol. 2016 May 17;67(19):2224-2234. doi: 10.1016/j.jacc.2016.02.064. Epub 2016 Apr 11.
9
Bleeding and ischemic events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients.在血液透析患者中,第二代药物洗脱支架植入后双联抗血小板治疗期间的出血和缺血事件。
J Cardiol. 2019 Jun;73(6):470-478. doi: 10.1016/j.jjcc.2018.12.009. Epub 2018 Dec 24.
10
Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.东亚患者经皮冠状动脉介入治疗后血小板反应性与缺血和出血事件的关系:PENDULUM 登记研究的 1 年结果。
J Am Heart Assoc. 2020 May 18;9(10):e015439. doi: 10.1161/JAHA.119.015439. Epub 2020 May 12.

引用本文的文献

1
Decoding Bleeding Risks and Survival in Patients Undergoing Percutaneous Coronary Intervention on Antiplatelet Therapy.解读接受抗血小板治疗的经皮冠状动脉介入治疗患者的出血风险和生存率
JACC Asia. 2025 Sep;5(9):1083-1094. doi: 10.1016/j.jacasi.2025.05.017. Epub 2025 Jul 29.
2
Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease: 2025 Update.《2025年东亚冠状动脉疾病患者抗血小板治疗立场声明更新版》
JACC Asia. 2025 Jul;5(7):821-846. doi: 10.1016/j.jacasi.2025.04.010.
3
Individual acute-phase bleeding and thrombotic risk balance assessment in patients undergoing percutaneous coronary intervention for acute myocardial infarction.
急性心肌梗死接受经皮冠状动脉介入治疗患者的个体急性期出血和血栓形成风险平衡评估
Am Heart J Plus. 2023 Mar 17;28:100292. doi: 10.1016/j.ahjo.2023.100292. eCollection 2023 Apr.
4
Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations.东亚人群急性冠状动脉综合征或经皮冠状动脉介入治疗后的抗栓治疗
JACC Asia. 2022 Feb 15;2(1):1-18. doi: 10.1016/j.jacasi.2021.12.005. eCollection 2022 Feb.
5
Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients.中国患者经皮冠状动脉介入治疗后大出血的发生率、预测因素及预后
JACC Asia. 2022 Apr 26;2(3):341-350. doi: 10.1016/j.jacasi.2021.12.009. eCollection 2022 Jun.
6
What Are Your Expectations for Risk Prediction Tools?您对风险预测工具的期望是什么?
JACC Asia. 2022 Apr 26;2(3):351-353. doi: 10.1016/j.jacasi.2022.01.003. eCollection 2022 Jun.
7
Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI.ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后基于普拉格雷的双联抗血小板治疗降阶梯方案
Korean Circ J. 2022 Apr;52(4):304-319. doi: 10.4070/kcj.2021.0293. Epub 2021 Dec 21.
8
Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease.肌肉减少症指数作为老年冠心病患者临床结局的预测指标
J Clin Med. 2020 Sep 27;9(10):3121. doi: 10.3390/jcm9103121.
9
Ethnic Differences in Oral Antithrombotic Therapy.口服抗血栓治疗中的种族差异。
Korean Circ J. 2020 Aug;50(8):645-657. doi: 10.4070/kcj.2020.0098.
10
Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia.急性冠状动脉综合征患者的抗栓策略:来自东亚的观点
J Clin Med. 2020 Jun 23;9(6):1963. doi: 10.3390/jcm9061963.